Friday, 16 October 2026European Markets

TOUR EIFFEL Stock 9.05% Up Today

Loading stream...

(vianews) - the market ended the session with tour eiffel (eiff.pa) rising 9.05% to €10.60 on thursday while cac 40 jumped 0.01% to €8,205.81.

tour eiffel's last close was €9.72, 46.3% below its 52-week high of €18.10.

about tour eiffel

with a property portfolio amounting to €1.7bn, société de la tour eiffel is an integrated property company with a strong culture of services. this agile company operates in various asset classes, including offices, urban logistics, managed residential and retail, in greater paris and other major french metropolitan areas. an active player throughout the property cycle, it assists its tenants - companies of all sizes and sectors - through high-standard direct management of its properties. société de la tour eiffel conducts a pro-active and transversal csr policy that is an integral part of its strategic orientations. société de la tour eiffel is listed on euronext paris (b board) - isin code: fr0000036816 - reuters: teif.pa - bloomberg: eiff.fp - member of the ieif foncières and ieif immobilier france indices.

earnings per share

as for profitability, tour eiffel has a trailing twelve months eps of €-0.65.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -1.54%.

volume

today's last reported volume for tour eiffel is 8467 which is 160.36% above its average volume of 3252.

moving average

tour eiffel's worth is way under its 50-day moving average of €12.45 and way below its 200-day moving average of €13.32.

more news about tour eiffel (eiff.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com